Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.
Jeffrey Bernstein, Ph.D., Elorac's President and CEO, commented, "We see a great market opportunity for Carbamide Peroxide in acne and rosacea. These are large markets. Branded topical products for acne and rosacea generate more than $1 billion in sales. CPO would be the first new topical product for acne and rosacea in several years. It's an improved, next-generation version of benzoyl peroxide (BPO), which is the most commonly used product for acne."
In two phase III pivotal double-blind, randomized, vehicle-controlled, paired-comparison, multi-center studies, the results showed statistically significant reductions in acne lesion counts after 8 and 12 weeks of treatment with CPO as compared to vehicle treatment.
Bernstein added, "The efficacy results for CPO are similar to those of previously approved topical acne products, but CPO has a distinct advantage in its tolerability. We have, in fact, clinical data comparing BPO and CPO in acne that demonstrates comparable efficacy, but documents significantly less local skin irritation in patients using CPO. We think that this superior tolerability also bodes well for the use of CPO in rosacea, where irritation is even more of an issue."